2014 Fiscal Year Final Research Report
Development of new cancer immunotherapy aiming activation of both anti-tumor killer and helper T cells
| Project/Area Number |
24300334
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor immunology
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
IRIE Atsushi 熊本大学, 大学院生命科学研究部, 講師 (30250343)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Keywords | がん免疫療法 / がん抗原 / ペプチドワクチン / キラーＴ細胞 / ヘルパーＴ細胞 / iPS細胞 |
|---|
| Outline of Final Research Achievements |
Two tumor-associated antigens, LY6K- and IMP3-derived long peptides (LP) that can be presented to CD4+ type 1 T helper (Th1) cells through multiple HLA class II molecules frequently observed in the Japanese population were identified. Using HLA-A2/A24-transgenic mice, vaccination of those LPs including short peptides (SP) that can activate tumor-reactive cytotoxic T lymphocytes (CTL) more efficiently induced CTLs than SP-vaccination did, suggesting the effectiveness of LPs for the improvement of anti-tumor immunotherapy.
Aiming the sufficient supply of antigen presenting cells, a protocol to produce large amount of dendritic cells (DC) from proliferative myeloid-lineage cells (ML) derived from human iPS cells was established. Furthermore, using the TAP-deficient ML, iPS-ML-DC that can escape from the recognition by the alloreactive CTLs was established. These iPS-ML-DC could efficiently present antigenic peptides to both CTLs and Th cells.
|
| Free Research Field |
腫瘍免疫学
|
